“Last three years have been volatile. This sector has seen very difficult times, we think we are coming out of those difficult phase,” Reliance Pharma Fund’s Sailesh Raj Bhan said.
"Also Indian companies are getting new product approvals, important products getting launched in the market place. I think the cycle certainly seems to have bottomed out for the US business,” he said.